1. Home
  2. FRO vs TGTX Comparison

FRO vs TGTX Comparison

Compare FRO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frontline Plc

FRO

Frontline Plc

HOLD

Current Price

$37.07

Market Cap

4.8B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$35.98

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRO
TGTX
Founded
1985
1993
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.9B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
FRO
TGTX
Price
$37.07
$35.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$37.67
$49.80
AVG Volume (30 Days)
2.9M
1.6M
Earning Date
05-22-2026
05-04-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
2.77
Revenue
N/A
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
N/A
$26.69
P/E Ratio
$34.05
$12.22
Revenue Growth
N/A
N/A
52 Week Low
$16.25
$25.37
52 Week High
$39.89
$40.99

Technical Indicators

Market Signals
Indicator
FRO
TGTX
Relative Strength Index (RSI) 60.35 58.82
Support Level $33.61 $32.95
Resistance Level $38.16 $37.92
Average True Range (ATR) 1.39 1.37
MACD 0.08 -0.30
Stochastic Oscillator 78.83 54.76

Price Performance

Historical Comparison
FRO
TGTX

About FRO Frontline Plc

Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: